SinoTherapeutics Inc. is a publicly traded specialty pharmaceutical company founded in 2012. Headquartered in Shanghai, China, the company operates a research and development center in Shanghai and manufacturing facilities in Haimen, Jiangsu Province. SinoTherapeutics is listed on the Shanghai Stock Exchange (SSE) under the ticker 688247 and has approximately 312 employees.
The company focuses on the research, development, and commercialization of complex and high-barrier generic drugs as well as innovative formulation products. Its product portfolio covers therapeutic areas such as oncology, infectious diseases, neurology, and metabolic disorders. Key products include Posaconazole delayed-release tablets, Bupropion extended-release tablets, and Metformin extended-release tablets. In addition to developing its own products, SinoTherapeutics provides contract research, development, and manufacturing (CRO/CDMO) services to other pharmaceutical companies.
As a pharmaceutical manufacturer, SinoTherapeutics is an operating company. The company's patent litigation history reflects a defensive posture, consistent with a generic drug manufacturer. The single tracked case is a patent infringement suit in which it is named as a defendant by a brand-name drug manufacturer, Astellas Pharma. This type of litigation is common in the pharmaceutical industry when a generic company files an Abbreviated New Drug Application (ANDA) to market a generic version of a branded drug.
The tracked case is Astellas Pharma Inc. et al. v. Haimen Pharma Inc. et al., filed in the U.S. District Court for the District of New Jersey in 2025. Haimen Pharma Inc. is a wholly-owned manufacturing facility of SinoTherapeutics. Public records indicate SinoTherapeutics has also been involved in other patent litigation typical for a generic drug maker, such as a 2021 lawsuit initiated by Pfizer to block a generic version of its drug Xeljanz XR.